This book provides a core understanding of the COVID-19 disease through ultrastructural imaging, using light microscopy, immunofluorescence, and scanning and transmission electron microscopy of samples from COVID-19 patients at different stages of the disease. It provides direct evidence of the impact of the SARS-CoV-2 virus on the cellular level in different age groups, disease stages, and comorbidities. The book explores advanced imaging techniques to enhance understanding of ultrastructural changes and provides a comprehensive overview of SARS-CoV-2-induced ultrastructural alterations in various respiratory tract cells. It summarizes key ultrastructural findings observed in SARS-CoV-2-infected cells, highlighting morphological and subcellular modifications, and features high-resolution images to illustrate virus-induced structural changes effectively.
The book includes contributions from academicians, scientists, and emerging researchers, ensuring an accessible yet in-depth presentation of the subject, and is a useful tool for everyone interested in understanding COVID-19.
This book provides a core understanding of the COVID-19 disease through ultrastructural imaging, using light microscopy, immunofluorescence, and scanning and transmission electron microscopy of samples from COVID-19 patients at different stages of the disease.
1. SARS-CoV-2 and COVID-19: An Ultrastructural Perspective
2.
Ultrastructural and Molecular Architecture of SARS-CoV-2
3. Tropism of
SARS-CoV-2: Microscopic Analysis
4. Impact of SARS-CoV-2 in the
Ultrastructure of Keratinized Oral Epithelium
5. Impact of SARS-CoV-2 in the
Ultrastructure of Non-Keratinized Oral Epithelium
6. Ultrastructure of
Different Cells of the Nasal Cavity of COVID-19 Patients
7. Ultrastructural
Alteration of Ciliated Epithelium of Bronchoalveolar Lavage Fluids
8.
Ultrastructural Variation of Type II Pneumocytes of BALF of COVID-19 Patients
9. Ultrastructural Modification of Alveolar Macrophage of BALF
10.
Ultrastructure of Lung-Infiltrated Neutrophils
11. Ultrastructural
Modification of Eosinophils in BALF of SARS-CoV-2 Patients
12.
Ultrastructural Proof of SARS-CoV-2 Infection in Lymphocytes
13.
Ultrastructural Modification of Anucleated Granulocytes in BALF
14.
SARS-CoV-2-Induced Formation of Single and Heterotypic Syncytial Cells: An
Ultrastructural Confirmation
15. Ultrastructural Evidence for the Impact of
Prophylactic Hydroxychloroquine on Impairment and Cellular SARS-CoV-2
Infection in Different Cells of BALF of COVID-19 Patients
16.
SARS-CoV-2-Induced Ultrastructural Changes in the Ciliated Epithelium, Type
II Pneumocytes, Macrophages, and Neutrophils of COVID-19 Patients
17.
Abnormal Ultrastructure Features on Type II Pneumocytes of COVID-19 Patients
with Aplastic Anemia
Subhash Chandra Yadav is an assistant professor of electron microscopy and nanotechnology at the All India Institute of Medical Sciences (AIIMS), New Delhi, India, since June 2015 and is currently working as an additional professor. He earned his PhD from the Institute of Medical Sciences, Banaras Hindu University (BHU), Varanasi, India. He has been a visiting researcher at Free University (FU) Berlin, Germany, and a postdoctoral fellow at the Indian Institute of Science (IISc), Bengaluru, India, and the University of Tennessee Medical Center, Knoxville, TN, USA. He has worked as a scientist in charge of the electron microscopy facility at the Institute of Himalayan Bioresource Technology (CSIR-IHBT) in Palampur, India, and the TERI-Deakin University Nanobiotechnology Centre. He has also been a visiting professor at Stanford University, USA. Dr Yadav has significantly utilized electron microscopy for the last 18 years to develop cost-effective and visual nanodiagnostic devices for prostate and cervical cancer and the BK virus, various nanoformulations for value addition, and targeted delivery vehicles. He worked extensively during the COVID-19 pandemic to explore the ultrastructural impact of SARS-CoV-2 infection in patients with acute respiratory distress syndrome (ARDS), including young and old patients with and without comorbidities, such as diabetes, liver and kidney disease, and malignancy.
